Fintel reports that on September 27, 2024, Raymond James initiated coverage of INmune Bio (NasdaqCM:INMB) with a Outperform recommendation.
Analyst Price Forecast Suggests 296.07% Upside
As of September 25, 2024, the average one-year price target for INmune Bio is $20.66/share. The forecasts range from a low of $16.16 to a high of $23.10. The average price target represents an increase of 296.07% from its latest reported closing price of $5.22 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for INmune Bio is 0MM, a decrease of 100.00%. The projected annual non-GAAP EPS is -2.07.
What is the Fund Sentiment?
There are 92 funds or institutions reporting positions in INmune Bio. This is an increase of 20 owner(s) or 27.78% in the last quarter. Average portfolio weight of all funds dedicated to INMB is 0.07%, an increase of 846.87%. Total shares owned by institutions increased in the last three months by 66.79% to 4,601K shares. 
The put/call ratio of INMB is 0.13, indicating a bullish outlook.
What are Other Shareholders Doing?
Cvi Holdings holds 596K shares representing 2.70% ownership of the company.
Praetorian PR holds 485K shares representing 2.19% ownership of the company.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 362K shares representing 1.64% ownership of the company. No change in the last quarter.
Geode Capital Management holds 323K shares representing 1.46% ownership of the company. In its prior filing, the firm reported owning 171K shares , representing an increase of 47.15%. The firm decreased its portfolio allocation in INMB by 29.62% over the last quarter.
Raymond James Financial Services Advisors holds 228K shares representing 1.03% ownership of the company.
INmune Bio Background Information
(This description is provided by the company.)
INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. The Natural Killer Cell Priming Platform includes INKmune™ aimed at priming the patient's NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic malignancies, solid tumors and chronic inflammation.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
